Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine

類似資料

• Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer
  著者:: Katoh, Masaru
  出版事項: (2018)
• Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
  著者:: Qin, Shuang, 等
  出版事項: (2019)
• Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
  著者:: Hyun Tae Lee, 等
  出版事項: (2019-03-01)
• Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
  著者:: Lee, Hyun Tae, 等
  出版事項: (2019)
• The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1
  著者:: Derosa, Lisa, 等
  出版事項: (2018)